Perioperative treatment with nivolumab and relatlimab provided long-term benefits in adults with stage III-IV, resectable melanoma.

Researchers recommended that regulators consider mandating head-to-head trials comparing next-in-class and against existing in-class agents when possible.

Researchers assessed the global burden of breast cancer in boys and men aged 15-64 years between 1990 and 2021.